Though most biopharma investment is in two states, follow this model to bring the research—and investments—elsewhere.

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

On the geopolitical front, the US-Russia talks on the Ukraine conflict add another layer of complexity. Should the ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries You have no doubt seen warnings that the U.S. stock market is ...

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Juventus’ financial future may be in the safest of hands after Paolo Ardoino, CEO of the Bianconeri’s new minority ...

Broking analysts have lowered their expectations on Cochlear, but in the main their valuations are above the current share ...